Literature DB >> 16367905

Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2.

Kumie Kage1, Toshiro Fujita, Yoshikazu Sugimoto.   

Abstract

Breast cancer resistance protein (BCRP/ABCG2) is a half-molecule ATP-binding cassette transporter that we have previously suggested might function as a homodimer, bridged by disulfide bonds. In the present study, we carried out cysteine-scanning mutagenesis, substituting Ser for Cys, and established 12 PA317 transfectants expressing BCRP mutants with possible disruptions to their S-S bonds. Western blot analysis of BCRP from the wild-type transfectants (PA/WT) confirmed that the wild-type protein migrates as a 140-kDa dimer under non-reducing conditions, but as a 70-kDa monomer under reducing conditions. However, under non-reducing conditions the BCRP-C603S mutant migrated both as a 70-kDa monomer and a 140-kDa dimer, whereas all other mutant BCRP migrated only as dimers. PA317 cells transfected with C603S-BCRP (PA/C603S) showed either similar or only marginally lower SN-38 resistance than PA/WT cells, despite the reduced levels of BCRP dimer in these cells. Moreover, the degree of SN-38 resistance in the mutant BCRP transfectants was found to be associated with the monomer expression levels under reducing conditions. Reverse transcription-polymerase chain reaction analysis showed that the BCRP mRNA levels were similar in the transfectants. We subsequently generated six C603X mutants of BCRP (X=D, H, R, Y, A and W) and carried out western blot analysis and drug sensitivity assays. The results were equivalent to those from the PA/C603S cells, with some variations that again corresponded to the monomer levels. Our findings suggest that Cys-603 is an important residue in the covalent bridge between BCRP monomers but that a functioning unit of BCRP may not necessarily require covalent linkages. (Cancer Sci 2005; 96: 866-872).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16367905     DOI: 10.1111/j.1349-7006.2005.00126.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  34 in total

1.  Recombinant synthesis of human ABCG2 expressed in the yeast Saccharomyces cerevisiae: an experimental methodological study.

Authors:  Anna Jacobs; Dana Emmert; Svenja Wieschrath; Christine A Hrycyna; Michael Wiese
Journal:  Protein J       Date:  2011-03       Impact factor: 2.371

2.  Kinesin-12, a mitotic microtubule-associated motor protein, impacts axonal growth, navigation, and branching.

Authors:  Mei Liu; Vidya C Nadar; Frank Kozielski; Marta Kozlowska; Wenqian Yu; Peter W Baas
Journal:  J Neurosci       Date:  2010-11-03       Impact factor: 6.167

Review 3.  Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Authors:  Dustin R Walsh; Thomas D Nolin; Peter A Friedman
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

4.  Structure of the human multidrug transporter ABCG2.

Authors:  Nicholas M I Taylor; Ioannis Manolaridis; Scott M Jackson; Julia Kowal; Henning Stahlberg; Kaspar P Locher
Journal:  Nature       Date:  2017-05-29       Impact factor: 49.962

5.  Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells.

Authors:  Zhanglin Ni; Michelle E Mark; Xiaokun Cai; Qingcheng Mao
Journal:  Int J Biochem Mol Biol       Date:  2010

6.  Localization of the placental BCRP/ABCG2 transporter to lipid rafts: Role for cholesterol in mediating efflux activity.

Authors:  John T Szilagyi; Anna M Vetrano; Jeffrey D Laskin; Lauren M Aleksunes
Journal:  Placenta       Date:  2017-04-12       Impact factor: 3.481

7.  Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.

Authors:  Tomoka Furukawa; Kanako Wakabayashi; Ai Tamura; Hiroshi Nakagawa; Yoshihiro Morishima; Yoichi Osawa; Toshihisa Ishikawa
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

8.  Gout-causing Q141K mutation in ABCG2 leads to instability of the nucleotide-binding domain and can be corrected with small molecules.

Authors:  Owen M Woodward; Deepali N Tukaye; Jinming Cui; Patrick Greenwell; Leeza M Constantoulakis; Benjamin S Parker; Anjana Rao; Michael Köttgen; Peter C Maloney; William B Guggino
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

9.  Mutational analysis of threonine 402 adjacent to the GXXXG dimerization motif in transmembrane segment 1 of ABCG2.

Authors:  Orsolya Polgar; Caterina Ierano; Akina Tamaki; Bradford Stanley; Yvona Ward; Di Xia; Nadya Tarasova; Robert W Robey; Susan E Bates
Journal:  Biochemistry       Date:  2010-03-16       Impact factor: 3.162

Review 10.  Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities.

Authors:  Macus Tien Kuo
Journal:  Antioxid Redox Signal       Date:  2009-01       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.